<DOC>
	<DOCNO>NCT02903498</DOCNO>
	<brief_summary>The purpose study evaluate efficacy tolerability maintenance treatment tegafur-uracil ( UFT ) standard first-line chemotherapy advance gastric cancer .</brief_summary>
	<brief_title>The Maintenance Treatment UFT Advanced Gastric Cancer</brief_title>
	<detailed_description />
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Tegafur</mesh_term>
	<criteria>Histologically confirm advanced metastatic adenocarcinoma stomach ECOG PS 02 At least one measurable evaluable lesion firstline chemotherapy ( 5FU base regimen : ECF/EOF/EOX/FOLFOX/XELOX ) efficacy evaluation nonPD Adequate hepatic , renal , heart , hematologic function ( platelet ≥75×109/L , neutrophil≥1.5×109/L , hemoglobin≥80 g/L , serum creatinine ≤1.5mg/dl , total bilirubin ≤1.5mg/dl , serum transaminase≤2.5×the ULN ) Receiving 2 regimen chemotherapy Pregnant lactate woman Concurrent cancer History malignancy except cure basal cell carcinoma skin carcinoma insitu uterine cervix Neuropathy , brain , leptomeningeal involvement Clinically relevant coronary artery disease history myocardial infarction within last 12 month high risk/uncontrolled arrhythmia Uncontrolled significant comorbid condition previous radiotherapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>disease control survival</keyword>
</DOC>